Skip to content

SHORT-TERM SUPRAORBITAL NERVE STIMULATION FOR TREATMENT OF SUBACUTE HERPETIC NEURALGIA IN THE FIRST BRANCH OF TRIGEMINAL NERVE

SHORT-TERM SUPRAORBITAL NERVE STIMULATION FOR TREATMENT OF SUBACUTE HERPETIC NEURALGIA IN THE FIRST BRANCH OF TRIGEMINAL NERVE

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016258
Enrollment
Unknown
Registered
2018-05-22
Start date
2018-05-31
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpetic Neuralgia

Interventions

A: supraorbital nerve block
B:short-term supraorbital nerve stimulation

Sponsors

First Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. aged >18 years old men and women; 2. clearly diagnosed as the herpetic neuralgia in the first branch of trigeminal nerve with typical neuralgia; 3. the duration of disease was limited to patients whose eruption time was greater than 2 weeks and less than 2 months; 4. voluntarily participated in this study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. women in pregnancy; 2. patients suffering from serious heart, brain, liver and body diseases can not tolerate minimally invasive surgery; 3. patients with abnormal coagulation function; 4. patients suffering from severe mental illness or other diseases can not correctly score the pain; 5. patients who were unable to follow up regularly; 6. allergy to the drugs in this study; 7. dissidents or unacceptable to this study.

Design outcomes

Primary

MeasureTime frame
visual analogue scale;pittsburgh sleep quality index, PSQI;

Countries

China

Contacts

Public ContactYan Liu

First Affiliated Hospital of China Medical University

liuyan176816482@163.com+86 15940257734

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026